Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma

Jan 11, 2022 | Press Releases

French regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first quarter of 2022 MARLBOROUGH, Mass., Jan. 11, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next...

Phio Pharmaceuticals Scheduled to Participate in the H.C. Wainwright Virtual BioConnect 2022 Conference

Jan 3, 2022 | Press Releases

MARLBOROUGH, Mass., Jan. 3, 2022 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Presents Positive New Data On Systemic Immune Response After Local PH-762 Therapy at the SITC 36th Annual Meeting

Nov 12, 2021 | Press Releases

MARLBOROUGH, Mass., Nov. 12, 2021 — Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

Nov 10, 2021 | Press Releases

Lead program, PH-762, is on track to enter first-in-human clinical study in Q1 2022Presented data at the ESMO Congress 2021 showing Dual-Targeting INTASYL PH-3861 induced a durable and specific systemic anti-tumor immune response following local...

Phio Pharmaceuticals Announces Upcoming Presentation at the SITC 36th Annual Meeting

Oct 18, 2021 | Press Releases

MARLBOROUGH, Mass., Oct. 18, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...

Phio Pharmaceuticals Presents New BRD4 Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 7, 2021 | Press Releases

MARLBOROUGH, Mass., Oct. 7, 2021 — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today...